CD Bioparticles launches custom cytokine detection services and assay kits

CD Bioparticles has expanded its immunology portfolio with custom services and specialized kits for detecting cytokines using homogeneous luminescence assay. The New York company says the platform is designed to speed up research in immunotherapy, vaccine development and drug discovery by replacing slower ELISA workflows.

Why it matters: - CD Bioparticles is targeting a major research bottleneck in cytokine testing: slow, hands-on ELISA workflows. - The new platform is designed to support faster work in immunotherapy, vaccine development and drug discovery. - The service offering could help researchers move from sample testing to assay development with fewer steps and lower sample volumes.

What happened: - CD Bioparticles launched high-throughput custom services and specialized kits for detecting cytokines with homogeneous luminescence assay. - The launch expands the company’s immunology portfolio. - The company said the service platform is available through its official service page: More information.

The details: - Cytokine detection uses a homogeneous luminescent platform that simplifies workflow by removing repeated washing steps. - Samples are added and incubated before testing, which reduces labor and time costs. - The kits are built for rapid, accurate, quantitative detection of cytokines in cell culture supernatants or serum samples. - The platform is designed to produce faster results with higher throughput and better automation compatibility than ELISA. - The method also offers higher sensitivity, a wider dynamic range and a lower risk of interference. - The assay requires smaller sample volumes and is suited to natural samples such as cell culture supernatants and serum. - CD Bioparticles offers development and testing services for homogeneous luminescent cytokine assay kits. - The service scope includes cytokine detection services, development of homogeneous luminescence assay kits, custom conjugation of antibodies or antigens with ligands and receptors, and assay validation. - The company says the offering can cover every stage from sample testing to development of complete homogeneous luminescence assay methods.

Between the lines: - The launch reflects broader demand for higher-throughput immunology tools that are easier to automate and less dependent on manual lab steps. - The emphasis on custom development suggests CD Bioparticles is positioning the platform for researchers with specialized assay requirements rather than only off-the-shelf use. - The focus on serum and cell culture supernatants points to applications in common preclinical and translational research workflows.

What's next: - Researchers can use the new services to discuss custom study protocols and assay design with CD Bioparticles. - The company is likely to use the platform to broaden its role in immunoassay development and related research services. - CD Bioparticles says the offering is available now through its service platform.

The bottom line: - CD Bioparticles is betting that homogeneous luminescence can replace some ELISA testing pain points with a faster, more flexible cytokine detection workflow.